Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioXcel Therapeutics's book value per share for the quarter that ended in Mar. 2026 was $-3.90.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of BioXcel Therapeutics was 47.20% per year. The lowest was 22.40% per year. And the median was 34.80% per year.
During the past 10 years, the highest P/B Ratio of BioXcel Therapeutics was 55.30. The lowest was 2.26. And the median was 11.04.
BioXcel Therapeutics (NAS:BTAI) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
BioXcel Therapeutics Book Value per Share Related Terms
BioXcel Therapeutics Book Value per Share Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTAI vs IXHL, SCYX, INIS: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAI) has a Book Value per Share of $-3.90 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Book Value per Share too high?
BioXcel Therapeutics' current Book Value per Share is $-3.90. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Book Value per Share compare to IXHL and SCYX?
BioXcel Therapeutics' Book Value per Share of $-3.90 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Book Value per Share is $-3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.66, compared to a current price of $0.85 — trading 29.1% above its estimated fair value. The current Book Value per Share is $-3.90. BioXcel Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Book Value per Share is $-3.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of $0.85 is trading 29.1% above its estimated GF Value™ of $0.66.
GuruFocus considers BioXcel Therapeutics to be Modestly Overvalued.
Key valuation signals for BTAI:
Book Value per Share: $-3.90
GF Value™: $0.66 vs. price of $0.85 (29.1% above fair value)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score
Get the complete analysis for BTAI
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
